论文部分内容阅读
瑞士制药巨头诺华(Novartis)近日公布了血癌药物Jakavi(ruxolitinib)一项关键III期临床研究RESPONSE研究的长期疗效和安全性数据。该研究在羟基脲耐药或不耐受的真性红细胞增多症(PV,简称“真红”)患者中开展,在研究的第18个月开展的一些既定分析显示,Jakavi治疗组有80%的患者实现红细胞压积受控(≤45%)而无需放血治疗同时脾脏体积得到缩小,且这种缓解至少持续了1年时间。同时,Jakavi治疗组有83%的患者在研究的第18个月仍在接受治疗,而最佳支持疗法(BSC)治疗组无一例继续治疗(0%)。相关数据已提交至6月
Novartis, the Swiss pharmaceutical giant, recently announced long-term efficacy and safety data from a pivotal phase III clinical study of the cancer drug Jakavi (ruxolitinib) in the RESPONSE study. The study was conducted in patients with hydroxyurea-resistant or intolerant polycythemia vera (PV). Some established analyzes conducted at the 18th month of the study showed that 80% of the patients in the Jakavi-treated group had 80 % Of patients achieved controlled hematocrit (<45%) without bleeding therapy while the spleen volume was reduced, and this remission lasted for at least 1 year. At the same time, 83% of patients in the Jakavi-treated group were still receiving treatment on the 18th month of the study, while none of the patients in the best-supportive-care (BSC) group continued treatment (0%). Relevant data has been submitted to June